Fourth Quarter 2023 Earnings

revvity

February 1, 2024

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways

Innovation	Transformation	Performance
Launched EONIS-Q to help automate SMA and SCID testing in newborns	Launched a new integrated E-Commerce platform in U.S. Advancing additional operational initiatives to drive greater synergies	Revenue upside was broad based in a challenging market environment Strong expense management & non-operating favorability

A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure

4Q23 Revenue Highlights

Segments

Diagnostics · Life Sciences



Geographic

AMERICAS · APAC · EU



Product Mix

RECURRING · NON-RECURRING



Revenue performance provided on a non-COVID organic basis

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2023 Revenue Highlights

Segments



Geographic



Product Mix



Revenue performance provided on a non-COVID organic basis

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

4Q23 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
$696M	**27.5%**	**$1.25**	**$196M**
⬇ -6% y/y	⬇ -480bps y/y	⬇ -11% y/y	⬆ +94% y/y
Organic: -7% | M&A: 0% | FX: 1%	Adj. Gross Margin: 60.2% | -360bps y/y	Adj. Tax Rate: 12.2%	Includes $7M of AES related inflows
Non-COVID: -3% organic growth		Adj. Net Interest & Other: $16M	
COVID: De minimis vs. $31M in 4Q'22			

2023 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
$2,751M	**28.0%**	**$4.65**	**$198M**
⬇ -17% y/y	⬇ -860bps y/y	⬇ -33% y/y	⬇ -66% y/y
Organic: -16% | M&A: 0% | FX: 0%	Adj. Gross Margin: 61.5% | -440bps y/y	Adj. Tax Rate: 18.6%	Includes $203M of AES related outflows
Non-COVID: +2% organic growth		Adj. Net Interest & Other: $58M	
COVID: $3M vs. $617M in FY22			

Life Sciences

Product



REVENUE	AJUSTED OP MARGINS
-9% Organic Growth	36.9%
Reported: -8% | M&A: 0% | FX: 1%	-500bps y/y

- -DD decline from Pharma/Biotech
- +HSD growth from Academic/Gov't
- Software decline due to contract renewal timing

Diagnostics

End Market



REVENUE	AJUSTED OP MARGINS
-6% Organic Growth	21.1%
Reported: -4% | M&A: 0% | FX: 1%	-760 bps y/y
Non-COVID Organic Growth: 3%	

- +Mid-teens ImmunoDX globally, China ImmunoDX +HSD
- Reproductive Health pressured by Revvity Omics contract timing
- -Mid-teens Non-COVID organic decline in Applied Genomics driven by instrumentation

2024 Financial Guidance

ADJ. REVENUE	**$2.79B - 2.85B**
	2% to 4% reported
	Organic: 1% to 3%
	FX: 1%, M&A: 0%
ADJUSTED OP. MARGIN	**~28%**
ADJUSTED EPS	**$4.55 - $4.75**
	Adj. Net interest expense, other: ~$70M
	Adjusted tax rate: ~20%
	Average diluted share count: 123.5M



Revvity.com